Foresight

Earlier this month CRBF was able to share our mission at Novartis Pharmaceutical in Boston. Novartis now owns the rights to Luxturna, a gene therapy that treats LCA-RPE65 blindness, in all countries...

You may have heard about the “One Word” movement. If not, basically, instead of making a New Year’s Resolution (or for many it’s in addition to the resolutions) you choose one word that you will...

The latest development in moving research forward for CRB1 LCA/RP retinal disease involves a collaborative effort between the CRBF, Sanford Research, and best of all… patients!  The CRB1 patient...

“Wow.” That’s pretty much the word first time attendees at BIO’s annual convention use, a lot. With over 17,000 people from 49 states and 67 countries in attendance, and expo booths bigger and more...